Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin + Paclitaxel in Advanced Urothelial Carcinoma
2006-002737-21Phase 2Active
- Sponsor
- Oncology Institute of Bari
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of gemcitabine, cisplatin and paclitaxel in transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Oncology Institute of Bari. Primary endpoints: Objective response rate and Duration of response. Started Jul 2007; status: active.
02
Drugs
gemcitabinecisplatinpaclitaxel
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2006-002737-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002737-21.